-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain ( "CINP" ) Phase 2b Trial ...

Something I love about Barry Ritholtz's writing is how he often surprises you with unexpected insights. Sure, he advances well-known - but still underappreciated - wisdom like how index fund investing is hard to beat and why making short-term market forecasts is futile.

Ayrmid submits an unsolicited takeover offer for Bluebird Bio. Bluebird Bio's board is currently reviewing the new offer with legal and financial advisors. Learn how to trade volatility during Q1 earnings season, live with Matt Maley on Wednesday, April 2 at 6 PM ET. Register for free now.

Investors can contact the law firm at no cost to learn more about recovering their losses

SOUTH SAN FRANCISCO, Calif., March 31, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced that members of the Company's management team are scheduled to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at ...

argenx ARGX has outperformed the market over the past 5 years by 17.3% on an annualized basis producing an average annual return of 34.95%. Currently, argenx has a market capitalization of $35.80 billion.

In the current session, the stock is trading at $86.77, after a 1.07% spike. Over the past month, Cava Group Inc. CAVA stock increased by 0.16%, and in the past year, by 31.38%.

Deep-pocketed investors have adopted a bullish approach towards Microsoft MSFT, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

Investors with a lot of money to spend have taken a bearish stance on Accenture ACN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

LOS ANGELES, March 31, 2025 /PRNewswire/ -- Acclaimed filmmaker Eli Roth's The Horror Section will officially launch its debut feature with the acquisition of Jimmy and Stiggs, directed by indie genre visionary Joe Begos - who also wrote and stars in the film - and produced in partnership with ...